Myocarditis Clinical Trials

Find Myocarditis Clinical Trials Near You

JOint Use of Database to Identify Risk Factors of CARDio-vascular Adverse Reactions Induced by Immune Checkpoint InhibiTors: VigiBase, Entrepot de Données de Santé (EDS), Système National Des Données de Santé (SNDS) Databases and a Retrospective International Multicenter Registry of ICI-associated Myocarditis

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events (irAEs) involving the cardio-vascular system. This study investigates reports of cardio-vascular toxicity associated with treatment including anti-PD1, Anti-PDL-1, and Anti CTLA4 classes using the World Health Organization (WHO) database VigiBase, Assistance Publique Hopitaux de Paris Entrepot de Données de Santé (APHP.EDS), French Système National Des Données de Santé (SNDS) Databases and a retrospective international multicenter registry of ICI-associated myocarditis

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Case reported in the World Health Organization (WHO) database of individual safety case reports to 01/01/2025

• Case reported in the APHP Entrepot de Données de Santé (EDS) database of individual safety case reports to 01/01/2025

• Case reported in the Système National Des Données de Santé (SNDS) Database of individual safety case reports to 01/01/2025

• Case reported in a retrospective international multicenter registry of ICI-associated myocarditis to 01/01/2025

• Adverse event reported were including the MedDRA terms: Cardiac and vascular investigations (excl enzyme tests) (HLGT), Vascular disorders (SOC), Skeletal and cardiac muscle analyses (HLT), Sudden death (PT), Sudden cardiac death (PT), Cardiac disorders (SOC), Cardiac arrhythmias (HLGT), Cardiac disorder signs and symptoms (HLGT), Cardiac neoplasms (HLGT), Cardiac valve disorders (HLGT), Congenital cardiac disorders (HLGT), Coronary artery disorders (HLGT), Endocardial disorders (HLGT), Heart failures (HLGT), Myocardial disorders (HLGT), Pericardial disorders (HLGT)

• Patients treated with ICIs included in the ATC: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32), Cemiplimab (L01XC33)

Locations
Other Locations
France
AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.
RECRUITING
Paris
Contact Information
Primary
Joe-Elie SALEM, MD PhD
joe-elie.salem@aphp.fr
142178531
Time Frame
Start Date: 2019-01-01
Estimated Completion Date: 2030-01-01
Participants
Target number of participants: 500000
Treatments
Myocarditis and other cardiovascular toxicities ICI-related
Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity
Non case
Non-case will be patients exposed to ICI without cardiovascular toxicities
Sponsors
Leads: Groupe Hospitalier Pitie-Salpetriere

This content was sourced from clinicaltrials.gov